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Bacitracins arc a group of widely used peptide antibiotics. There has been interest in determining the three-dimensional structure of the bacitracins. 
However, solution studies indicate significant flexibility in their structure and to date native bacitracins have resisted attempts at crystallisation 
despite considerable efforts over a number of years by several groups. Here we report the first three-dimensional X-ray structure of a bacitracin, 
complexed to a subtilisin proteinase. X-Ray diffraction data were collected using synchrotron radiation in combination with the Image Plate Scanner 
system. The complex structure including two enzymes, two bacitracins, 220 water molecules and two Caz+ ions was refined by restrained least- 
squares to a crystallographic R factor (=z{{F,-F,}}/C{F,}}) of 16.3% at 2.0 A. 
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1. INTRODUCTION 
The bacitracins are a group of widely used broad 
spectrum antibiotics [l-3]. They are a set of closed 
related cyclic dodecapeptides, termed bacitracin A, B, 
C, D, E, and F, produced by a strain of BaciNus 
/iclzen~omis [4,5]. This article refers only to bacitracin 
A (Fig. 1). The bacitracins have certain special struc- 
tural features. Firstly there are four right-handed D- 
amino acids alternating with the usual L-amino acids 
along the peptide chain. Secondly, the several charged 
side chains enhance the possibility of interaction with 
other proteins. Thirdly, there is a thiazoline ring close 
to the N-terminus. The thiazoline ring is though to be 
synthesized by a cyclic condensation of the isoleucylcys- 
teine moiety during the process of bacitracin biosyn- 
thesis [6,7]. Fourthly, the side chain of L-Lys-6 forms a 
link to the chain of L-Asn-12, producing a cyclic struc- 
ture. Bacitracins are widely used in chemotherapy 
because of their antibacterial action mainly due to their 
inhibition of specific enzymes during bacterial cell wall 
biosynthesis in Gram-positive bacteria [g-lo]. They are 
in fact multifunctional peptides and have a number of 
other interesting properties. For example, they can in- 
teract with the large groove of DNA by means of 
hydrogen bonds [l 11. Bacitracin A can also chelate a 
single zinc ion. The cyclic structure and the presence of 
four D-amino acids, are assumed to give them special 
*Coordinates of bacitracin A, as well as the coordinates of the whole 
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conformation(s) explaining their resistance to 
hydrolysis by the majority of proteinase, and to be a 
potential inhibitor towards proteinases. The kinetic 
constant for the inhibition (Ki) of subtilisin enzymes by 
bacitracin is relatively low and lies in the range of 5 mM 
as determined with Sue-2-Ala-Phe-p-NPA as substrate 
[ 121. This explains also the use of bacitracin A as a sor- 
bent in affinity chromatography based on its interacting 
selectively as inhibitor with certain hydrolytic enzymes, 
including the subtilisins [13,14]. This property has been 
exploited here to co-crystallise bacitracin A with Savi- 
nase, an alkaline subtilisin from Bacillus Ientus [15]. 
The enzyme is highly homologous to subtilisins Carls- 
berg and BPN’ [l&-19]. The native structure has been 
refined at 1.4 p\ resolution [20]. Bacitracin A and zinc- 
bacitracin A both inhibit this enzyme by forming 
stoichiometric 1: 1 non-covalent complexes. The 
molecular weights of the two complexes were analysed 
in solution by centrifugation and ultra-filtration. The 
results gave an unusually high molecular weight, twice 
the molecular weight of one 1: I complex. 
2. MATERIAL AND METHODS 
Zinc-bacitracin A was purchased from Aldrich-Chemie and the 
Bm’llm /c~7rus Savinase was provided by NOVO-NORDISK (Copen- 
hagen, Denmark). Crystals OF the zinc-bacitracin/Savinase complex 
were grown by vapour diffusion [21]. A 5: 1 molar ratio of inhibitor 
and enzyme was used. Crystals were grown at 18°C at 0.5 M citrate, 
pH 6.0, 12% polyethylene glycol 8000, 0.5 M NaCl and 5 mM CaClz 
using a precipitant and buffer concentration of 50% of the well con- 
centration [24]. For X-ray studies, sin& crystals were mounted in 0.7 
mm diameter thin-walled glass capilarry tubes. The crystals grow in 
space group C2 with cell dimension a = 105.4 A, b = 60.6 A, c = 95. I 
A, B= 117.3’ for the zinc-bacitracin/Savinase complex (V,,,=2.64 
A’/Da). X-Ray data to 2.0 A resolution were collected at the storage 
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Fig. 1. The chemical fcrmula of Bacitracin A. The molecular weight 
is 1450 dalton. The region presented in detail consists of an isoleucine 
and a cysteine residue, condensed to form a thiazoline ring rather than 
the usual peptide linkzge. The charges shown are for the molecule at 
neutral pH. 
ring DORIS at DESY using the EMBL image plate scanner. The in- 
tensity data have a merging Rrgm factor, defined as Rrym= CE 
[I - li]/CSli where J is the mean value of i intensity observations /i of 
6.5%. The structure was solved by molecular replacement. The 
special features of bacitracin were taken into consideration as addi- 
tional restraints in the refinement. The final R value was 16.3% for 
all data in the range of X0-8.0 A. The model contains all atoms of 
the enzyme and of the bacitracin escluding the N-terminal residue 
lie-l for both chains I and II because of very weak electron density. 
220 solvent molecules and two Ca*’ ions bound to the enzyme were 
included. The RMS deviations from ideal values for bond lenghts. 
peptide planes, chiral centres and bond angles are 0.018 A. 0.01 A, 
0.223 and 2.3”. respectively. Details of the structure analysis will be 
published later. The biochemical experiments to analyst whether the 
zinc is still bound to the bacitracin in solution were performed by 
spectroscopy in the Chemistry Department of the University of Ham- 
burg. 
3. RESULTS 
The complex of Savinase with zinc-bacitracin A was 
crystallized and the structure refind (Fig. 2). The model 
provides the first crystal structure of a bacitracin and 
shows a novel mode of inhibition of a subtilisin, fun- 
damentally different to that observed with other natural 
or synthetic inhibitors to date. Ths complex is formed 
from two enzyme molecules (referred to as A and l3) 
linked by two bacitracin molecules (I and II) (Fig. 3 and 
4). Each bacitracin A molecule binds non-covalently to 
the catalytic site of one Savinase and the substrate bin- 
ding region of the second, such that the active sites of 
the two molecules face one another. The interaction of 
bacitracin with the active site is through the D-Glu-4 
side chain forming hydrogen bonds to the catalytic site 
atoms NE1 of His-64 and OG of Ser-221 (the number- 
ing is that of the reference structure subtilisin BPN’), to 
the oxyanion-holeforming side chain of Asn-145, the 
main chain N of Ser-221 and to the carbonyl oxygen of 
Asn-218 (Fig. 2). The links to the second enzyme are 
through direct I-I-bonds with the substrate binding 
region or bridges via water molecules. For both enzyme 
molecules the structure remains as in the native protein, 
and the geometry of the active site is not perturbed. The 
hydrogen bonding in the active site is as found in the ac- 
tive conformation and shown in Figs. 2 and 4. 
Parts of bacitracins I and II differ significantly in 
conformation in the complex. For both, the two N- 
terminal residues and the thiazoline ring are somewhat 
disordered with rather weak electron density. From 
residue 3 onwards the electron density is well defined. 
In bacitracin I the main chain lies in a extended confor- 
mation from residue 4 to 8 leading enzyme A to B. The 
side chain of D-Phe-9 fits smoothly into the substrate 
binding site formed by the strands 99-104 and 125-131 
of Savinase, which normally bind the main chain of the 
Fig. 4. Stereo-view of the binding of the two bacitracin molecules (labelled I and II) to the active sites of the enzymes (A and B). The !>acitracins 
are shown in thick lines, and in thinner lines those residues of the enzyme involved in the interaction. The linkage between N.? of L-Lys and the 
C atom of L-Asn is also shown in thinner lines. Solvent molecules are indicated as circles. Hydrogen bonds are dashed. The positions where the 
two bacitracin peptides begin to differ in conformation are marked with arrows. The specific recognition and binding apears to be in the active 
site region. 
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Fig. 2. View of the (2F,-F,) electron density showing that part of the bacitracin A chain interacting with the active site of the enz>‘me. 
Fig. 3. A ribbon plot of the bacitracin/Savinase complex. 
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substrate or inhibitor by forming an antiparallel P- 
structure. The last three residues of bacitracin I form a 
bend towards the Pl site of the same enzyme. The C- 
terminal residue Eeu-12 makes the e linkage with 
L-Lys-6. 
Bacitracin II lies in a similar position in the active site 
of enzyme molecule B. Up to residue 8 the conforma- 
tion is extended as in bacitracin I. However, the confor- 
mation of the loop of residues 8-l 1 is nearly opposite 
to that in molecule I (Fig. 4). The D-Phe-9 side chain is 
not located in the substrate binding region but is 
directed away from the surface of the enzyme. The side 
chain of His-10 instead forms a weak hydrogen bond 
with the Ser-130 in this region of the enzyme. Even 
though the chain folding of the two bacitracins is dif- 
ferent the contacts to contracts to the enzyme are rather 
similar. All contracts via H-bonds are summarised in 
Table I. 
4. DISCUSSION 
No zinc ions could be located in the three-dimen- 
sional structure, even though zinc-bacitracin was used 
in the co-crystallisation. A sample of zinc-bacitracin 
was dissolved in crystallisation buffer and dialysed 
against the same buffer. Spectroscopic analysis in- 
dicated that zinc remained complexed to bacitracin in 
solution and was not removed by dialysis. NMR techni- 
ques [Z-Z] indicated that at pH 5.0 three groups in 
the bacitracin bind to the zinc cation: the thiazoline 
ring, Glu-4, and His-IO. In the complex described here 
these groups lie far away from one another, two of 
Table I 
The whole direct hydrogen bond interaction of the two bacitracin chains with the two cn- 
zyme molecules is listed together with the hydrogen bonds via water molecules 
Bacitracin Enzyme 
Atom Residue/Chain Atom Residue Molecule Distance(A) 
0 
N 
OE2 
052 
OE2 
Ocl 
061 
0 
0 
0 
N 
0 
0 
0 
N 
Na2 
oal 
0a1 
oa1 
0 
0 
N 
N 
0<2 
062 
Of2 
Otl 
Of1 
Nj_ 
N 
N 
0 
NC31 
082 
Na2 
Na2 
oai 
21 
41 
41 
41 
41 
41 
41 
5 I z.rs-OW317 h-3.15 
5 I 3,2,-OW52S B-3.~~ 
5 1 n,z~-OW525 B-3.23 
81 
81 
9 I 2.wOW561 B-~.zI 
91 :.wOWS61 B-Z.HJ 
10 I 
12 I 2,s~OW315 B-2.9, 
12 I z.two~38~ &AI 
12 1 z.ss-ow384 B-2.57 
12 I 
2 II 
2 II 3.2~0W348 B-z.~ 
4 II n.za-OW348 B-2.~7 
4 II 
4 II 
4 II 
4 II 
4 II 
4 II 
6 II 
7 II j.“s-OW324 B-3.13 
9 II 
9 II z.wOW359 8-3.0s 
10 II 
11 II 
12 II 
12 II 3.wOW350 B-2.9s 
12 II 3.2~OWS38 A-2.99 
Na2 218 
0 218 
Na2 1.55 
OY 221 
N 221 
NP~ 64 
OY 221 
Na2 62 
0 99 
Na2 62 
0 100 
N 12? 
N 102 
0 IO2 
0 127 
OY 221 
Or I6G 
Nc2 191 
N 155 
Na2 218 
N 218 
N 218 
0 218 
OY 221 
Na2 155 
N 221 
Nc2 64 
OY 221 
N 216 
0 127 
0 102 
N 104 
0 130 
OY 130 
0 214 
Ne2 20G 
OYl 213 
A 2.77 
A 2.95 
A 2.65 
A 2.85 
A 3.29 
A 2.79 
A 2.62 
A 
A 
A 
B 2.73 
B 2.97 
B 
B 
B 2.92 
R 
B 
B 
B 2.89 
B 2.60 
B 
B 
B 3.04 
B 2.64 
B 2.67 
B 3.29 
B 2.64 
B 2.99 
B 2.99 
.4 
A 2.82 
A 
A 3.27 
A 2.83 
B 2.85 
B 
B 
The distances are given in A. For the interaction via water molecules the distances are given 
in subscript. 
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them indeed making contacts with different Savinase 
molecules. Thus bacitrasin A seems to undergo confor- 
mational changes on binding to Savinase involving the 
parallel release of the zinc cation. This is in keeping 
with the interaction of the negatively charged side chain 
of D-Glu-4, probably the most important residue in ca- 
tion binding, with the active site of Savinase in the com- 
phX. 
Although their electron density is wall defined, both 
bacitracins I and II have relatively high atomic temper- 
ature factors, indicating significant flexibility in their 
structure. The average B value for the bacitracins is 25.4 
AZ, that of the Savinase 17.1 A’. The highest flexibility 
is observed for amino acids not involved in hydrogen 
bonds. Flexibility in the structure is also seen in the dif- 
ference in conformation between bacitracin molecules I 
and II, and the loss of zinc ion, with presumed change 
in conformation, on complex formation. Bacitracin A 
is clearly able to take up a number of different confor- 
mations depending on the local environment and the 
dynamic nature of the structure is certainly related to 
the multifunctional properties of this fascinating 
molecule. The crystal analysis at least permits two 
allowed conformations to be identified. The three- 
dimensional structure will serve as an essential basis for 
the understanding of the mechanism and action of 
bacitracin. 
nck,zo,v/edgenlenr: This study was supported by a FEBS Stipendium 
for Sabine Pfeffer. 
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